Valeant, Norgine partner for bowel-cleansing solution; EndoChoice's Q2 net loss totals $24.7M: 3 GI company key notes

Here are three recent news updates on key gastroenterology and endoscopy companies.

Valeant Pharmaceuticals entered into a licensing agreement with Norgine for a bowel-cleansing oral solution used to prepare for colonoscopies.

EndoChoice reported total revenue for the second quarter of 2016 was $19.3 million, but net loss for the second quarter totaled $24.7 million.

EndoChoice's Lumos received FDA clearance and was recently launched in the United States.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast